EGFR and cancer: Generally, KRAS and BRAF mutations are mutually exclusive, moreover, BRAF indicates poorer prognosis for mCRC patients treated with anti-EGFR therapy16, while the role of BRAF in other cancer stage is still unclear, reported studies did not sustain accordance about this issue17, 18, 19, 20.